🔎 Trials Near Me

Beranda › Karsinoma Sel Skuamosa › Tennessee

Uji klinis Karsinoma Sel Skuamosa di Tennessee

7 studi untuk Karsinoma Sel Skuamosa mencari peserta di lokasi di Tennessee.

Kota di Tennessee

Teks studi resmi (Bahasa Inggris)

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

  • Vanderbilt University Medical Center, Nashville
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06047379

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

  • Sarah Cannon Research Institute, Nashville
  • SCRI Oncology Partners, Nashville
  • Vanderbilt-Ingram Cancer Center, Nashville
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06561685

Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer

  • Vanderbilt University Medical Center, Nashville
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT06819228

Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

  • Vanderbilt University Medical Center, Nashville
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Jul 2026 · NCT07460765

Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma

  • Vanderbilt University Medical Center, Nashville
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Mei 2026 · NCT07217028

High-Resolution PET-CT Imaging for Surgical Margin Visualization

  • Vanderbilt University Medical Center, Nashville
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Mei 2026 · NCT06915454

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

  • Vanderbilt University Medical Center, Nashville
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Agu 2025 · NCT04429542

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.